1
|
Mao W, Jiang F, Zhu C, Liu J, Lu Z, Qian Y, Xiao J. Effect of CTLA-4 Inhibition on Inflammation and Apoptosis After Spinal Cord Injury. Neurochem Res 2024; 49:1359-1372. [PMID: 38366208 DOI: 10.1007/s11064-024-04121-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Revised: 01/18/2024] [Accepted: 02/04/2024] [Indexed: 02/18/2024]
Abstract
Spinal cord injury (SCI) encompasses various pathological processes, notably neuroinflammation and apoptosis, both of which play significant roles. CTLA-4, a well-known immune molecule that suppresses T cell-mediated immune responses, is a key area of research and a focal point for targeted therapy development in treating tumors and autoimmune disorders. Despite its prominence, the impact of CTLA-4 inhibition on inflammation and apoptosis subsequent to SCI remains unexplored. This study aimed to investigate the influence of CTLA-4 on SCI. A weight-drop technique was used to establish a rat model of SCI. To examine the safeguarding effect of CTLA-4 on the restoration of motor function in rats with SCI, the Basso-Beattie-Bresnahan (BBB) scale and inclined plane test were employed to assess locomotion. Neuronal degeneration and apoptosis were assessed using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) and Fluoro-Jade B labeling, respectively, and the activity of microglial cells was examined by immunofluorescence. To evaluate the impact of CTLA4 on SCI, the levels of inflammatory markers were measured. After treatment with the CTLA-4 inhibitor ipilimumab, the rats showed worse neurological impairment and more severe neuroinflammation after SCI. Furthermore, the combination therapy with ipilimumab and durvalumab after SCI had more pronounced effects than treatment with either inhibitor alone. These findings indicate that CTLA-4 contributes to neuroinflammation and apoptosis after SCI, presenting a promising new therapeutic target for this traumatic condition.
Collapse
Affiliation(s)
- Wei Mao
- Department of Orthopedics, The Third People's Hospital of Zhangjiagang, 8 People's Road of Tang bridge town, Zhangjiagang, Suzhou, Jiangsu, 215611, P.R. China
| | - Feng Jiang
- Department of Neurosurgery and Translational Medicine center, The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, 215600, P.R. China
| | - Chunping Zhu
- Department of Orthopedics, The Third People's Hospital of Zhangjiagang, 8 People's Road of Tang bridge town, Zhangjiagang, Suzhou, Jiangsu, 215611, P.R. China.
| | - Jun Liu
- Department of Orthopedics, The Third People's Hospital of Zhangjiagang, 8 People's Road of Tang bridge town, Zhangjiagang, Suzhou, Jiangsu, 215611, P.R. China
| | - Zhao Lu
- Department of Orthopedics, The Third People's Hospital of Zhangjiagang, 8 People's Road of Tang bridge town, Zhangjiagang, Suzhou, Jiangsu, 215611, P.R. China
| | - Yinwei Qian
- Department of Orthopedics, The Third People's Hospital of Zhangjiagang, 8 People's Road of Tang bridge town, Zhangjiagang, Suzhou, Jiangsu, 215611, P.R. China
| | - Jinchun Xiao
- Department of Orthopedics, The Third People's Hospital of Zhangjiagang, 8 People's Road of Tang bridge town, Zhangjiagang, Suzhou, Jiangsu, 215611, P.R. China.
| |
Collapse
|
2
|
Wang LC, Tsai HP, Chen SH, Wang SM. Therapeutics for fulminant hepatitis caused by enteroviruses in neonates. Front Pharmacol 2022; 13:1014823. [DOI: 10.3389/fphar.2022.1014823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 10/04/2022] [Indexed: 11/13/2022] Open
Abstract
Neonatal infection with nonpolio enteroviruses (EVs) causes nonspecific febrile illnesses and even life-threatening multiorgan failure. Hepatitis, which often results in hepatic necrosis followed by disseminated intravascular coagulopathy, is one of the most severe and frequent fatal neonatal EV infection complications. Coxsackievirus B (CVB) 1–5 and many echoviruses have been most commonly identified. Neonatal EV infection treatment has usually involved initial supportive care. Studies for CVB and echovirus infection treatments were developed for more than thirty years. Intravenous immunoglobulin and pleconaril therapy was performed in some clinical trials. Additionally, other studies demonstrated antiviral and/or anti-inflammatory pathogenesis mechanisms of neonatal EV hepatitis in in vitro or in vivo models. These treatments represented promising options for the clinical practice of neonatal EV hepatitis. However, further investigation is needed to elucidate the whole therapeutic potential and safety problems.
Collapse
|
3
|
Cleavage of AUF1 by Coxsackievirus B Affects DDX5 Regulatory on Viral Replication through iTRAQ Proteomics Analysis. BIOMED RESEARCH INTERNATIONAL 2022; 2022:8610467. [PMID: 36246972 PMCID: PMC9560859 DOI: 10.1155/2022/8610467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 09/09/2022] [Indexed: 11/18/2022]
Abstract
Coxsackievirus B (CVB) 3C protease (3Cpro) plays a specific cleavage role on AU-rich binding factor (AUF1, also called hnRNP D), which consequently disputes the regulation of AUF1 on downstream molecules. In our study, the iTRAQ approach was first used to quantify the differentially expressed cellular proteins in AUF1-overexpressing HeLa cells, which provides straightforward insight into the role of AUF1 during viral infection. A total of 1,290 differentially expressed proteins (DEPs), including 882 upregulated and 408 downregulated proteins, were identified. The DEPs are involved in a variety of cellular processes via GO terms, protein–protein interactions, and a series of further bioinformatics analyses. Among the DEPs, some demonstrated important roles in cellular metabolism. In particular, DDX5 was further verified to be negatively regulated by AUF1 and increased in CVB-infected cells, which in turn promoted CVB replication. These findings provide potential novel ideas for exploring new antiviral therapy targets.
Collapse
|
4
|
Selina PI, Karaseva MA, Komissarov AA, Safina DR, Lunina NA, Roschina MP, Sverdlov ED, Demidyuk IV, Kostrov SV. Embryotoxic activity of 3C protease of human hepatitis A virus in developing Danio rerio embryos. Sci Rep 2021; 11:18196. [PMID: 34521911 PMCID: PMC8440601 DOI: 10.1038/s41598-021-97641-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 08/27/2021] [Indexed: 11/23/2022] Open
Abstract
The 3C protease is a key factor in picornavirus-induced pathologies with a comprehensive action on cell targets. However, the effects induced by the enzyme have not been described at the organismic level. Here, the model of developing Danio rerio embryos was used to analyze possible toxic effects of the 3C protease of human hepatitis A virus (3Cpro) at the whole-body level. The transient 3Cpro expression had a notable lethal effect and induced a number of specific abnormalities in Danio rerio embryos within 24 h. These effects are due to the proteolytic activity of the enzyme. At the same time, the 3Cpro variant with reduced catalytic activity (3Cmut) increased the incidence of embryonic abnormalities; however, this effect was smaller compared to the native enzyme form. While the expression of 3Cmut increased the overall rate of abnormalities, no predominance of specific ones was observed. The data obtained point to a presence significant impact of picornavirus 3Cprotease at the whole-organism level and make contribution to the study of the infectious process caused by human hepatitis A virus.
Collapse
Affiliation(s)
- Polina I Selina
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia.
| | - Maria A Karaseva
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| | - Alexey A Komissarov
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| | - Dina R Safina
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| | - Nataliya A Lunina
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| | - Marina P Roschina
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| | - Eugene D Sverdlov
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| | - Ilya V Demidyuk
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| | - Sergey V Kostrov
- Institute of Molecular Genetics of National Research Center, Kurchatov Institute, 123182, Moscow, Russia
| |
Collapse
|
5
|
The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. Cancers (Basel) 2021; 13:cancers13174426. [PMID: 34503236 PMCID: PMC8431622 DOI: 10.3390/cancers13174426] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 07/29/2021] [Accepted: 08/16/2021] [Indexed: 12/17/2022] Open
Abstract
Tumor cells can evade the immune system via multiple mechanisms, including the dysregulation of the immune checkpoint signaling. These signaling molecules are important factors that can either stimulate or inhibit tumor immune response. Under normal physiological conditions, the interaction between programmed cell death ligand 1 (PD-L1) and its receptor, programmed cell death 1 (PD-1), negatively regulates T cell function. In cancer cells, high expression of PD-L1 plays a key role in cancer evasion of the immune surveillance and seems to be correlated with clinical response to immunotherapy. As such, it is important to understand various mechanisms by which PD-L1 is regulated. In this review article, we provide an up-to-date review of the different mechanisms that regulate PD-L1 expression in cancer. We will focus on the roles of oncogenic signals (c-Myc, EML4-ALK, K-ras and p53 mutants), growth factor receptors (EGFR and FGFR), and redox signaling in the regulation of PD-L1 expression and discuss their clinical relevance and therapeutic implications. These oncogenic signalings have common and distinct regulatory mechanisms and can also cooperatively control tumor PD-L1 expression. Finally, strategies to target PD-L1 expression in tumor microenvironment including combination therapies will be also discussed.
Collapse
|
6
|
Liu K, Wang J, Gao X, Ren W. C1q/TNF-Related Protein 9 Inhibits Coxsackievirus B3-Induced Injury in Cardiomyocytes through NF- κB and TGF- β1/Smad2/3 by Modulating THBS1. Mediators Inflamm 2020; 2020:2540687. [PMID: 33414684 PMCID: PMC7769632 DOI: 10.1155/2020/2540687] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 11/24/2020] [Accepted: 12/07/2020] [Indexed: 12/12/2022] Open
Abstract
C1q/TNF-related protein 9 (CTRP9) is implicated in diverse cardiovascular diseases, but its role in viral myocarditis (VMC) is not well explored. This study is aimed at investigating the role and potential mechanism of CTRP9 in VMC. Herein, we found that the peripheral blood collected from children with VMC had lower CTRP9 levels than that from children who had recovered from VMC. H9c2 cardiomyocytes treated with coxsackievirus B3 (CVB3) were applied to establish a VMC model in vitro, and the expression of CTRP9 was significantly decreased in CVB3-induced H9c2 cells. The overexpression of CTRP9 attenuated CVB3-induced apoptosis, inflammation, and fibrosis reactions in H9c2 cells by promoting cell proliferation, reducing the cell apoptosis rate, and inhibiting inflammatory cytokine levels and fibrosis-related gene expression. Moreover, we found that thrombospondin 1 (THBS1) levels were increased in children with VMC, and CTRP9 negatively regulated THBS1 expression by interacting with THBS1. The downregulation of THBS1 inhibited CVB3-induced apoptosis, inflammation, and fibrosis in H9c2 cells. In addition, our mechanistic investigation indicated that the overexpression of THBS1 impaired the inhibitory effect of CTRP9 on CVB3-induced H9c2 cells. The results further revealed that the CVB3-induced NF-κB and TGF-β1/Smad2/3 signaling pathways of H9c2 cells were blocked by CTRP9 yet activated by THBS1. In conclusion, CTRP9 protected H9c2 cells from CVB3-induced injury via the NF-κB and TGF-β1/Smad2/3 signaling pathways by modulating THBS1.
Collapse
Affiliation(s)
- Kebei Liu
- Department of Internal Medicine, Xi'an Children's Hospital, Xi'an, Shaanxi 710003, China
| | - Juan Wang
- Department of Clinical Laboratory, Xi'an Children's Hospital, Xi'an, Shaanxi 710003, China
| | - Xinru Gao
- Department of Medical Ultrasound Center, The Northwest Women's and Children's Hospital, Xi'an, Shaanxi 710003, China
| | - Wei Ren
- Department of Internal Medicine, Xi'an Children's Hospital, Xi'an, Shaanxi 710003, China
| |
Collapse
|
7
|
Mirabel M, Callon D, Bruneval P, Lebreil AL, Mousseaux E, Oudard S, Hulot JS, Andreoletti L. Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. JACC: CARDIOONCOLOGY 2020; 2:511-514. [PMID: 34396260 PMCID: PMC8352190 DOI: 10.1016/j.jaccao.2020.05.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 05/28/2020] [Accepted: 05/29/2020] [Indexed: 12/26/2022]
Affiliation(s)
- Mariana Mirabel
- Université de Paris, Paris Cardiovascular Research Center PARCC, INSERM, Paris, France.,Cardio-oncology unit, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Domitille Callon
- Université de Reims Champagne Ardenne, Cardiovir EA-4684, Reims, France.,CHU Reims, Hôpital Robert Debré, Pathology Department, Reims, France
| | - Patrick Bruneval
- Université de Paris, Paris Cardiovascular Research Center PARCC, INSERM, Paris, France.,Assistance Publique-Hôpitaux de Paris, APHP Centre, Hôpital Européen Georges Pompidou, Pathology, Paris, France
| | | | - Elie Mousseaux
- Université de Paris, Paris Cardiovascular Research Center PARCC, INSERM, Paris, France.,Cardio-vascular imaging, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Stéphane Oudard
- Université de Paris, Paris Cardiovascular Research Center PARCC, INSERM, Paris, France.,Medical Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Jean-Sébastien Hulot
- Université de Paris, Paris Cardiovascular Research Center PARCC, INSERM, Paris, France.,Cardio-oncology unit, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.,Centre d'Investigations Cliniques CIC1418, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
| | - Laurent Andreoletti
- Université de Reims Champagne Ardenne, Cardiovir EA-4684, Reims, France.,CHU Reims, Hôpital Robert Debré, Virology Department, Reims, France
| |
Collapse
|